Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021

BACKGROUND: Direct-acting antivirals (DAAs) for hepatitis C treatment in China became available since 2017. This study expects to generate evidence to inform decision-making in a nationwide scale-up of DAA treatment in China. METHODS: We described the number of standard DAA treatment at both nationa...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xinyu, Mi, Jiarun, Cheng, Hanchao, Song, Yuanyuan, Li, Yuchang, Sun, Jing, Chan, Polin, Chen, Zhongdan, Luo, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043849/
https://www.ncbi.nlm.nih.gov/pubmed/36978198
http://dx.doi.org/10.1186/s40249-023-01081-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043849/
https://www.ncbi.nlm.nih.gov/pubmed/36978198
http://dx.doi.org/10.1186/s40249-023-01081-4

Ejemplares similares